Everolimus‐facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2‐year results from the subgroup analysis of the TRANSFORM study

We analyzed the efficacy and safety of an everolimus with reduced‐exposure calcineurin inhibitor (EVR+rCNI) versus mycophenolic acid with standard‐exposure CNI (MPA+sCNI) regimen in Asian patients from the TRANSFORM study.

[1]  S. Chadban,et al.  Two‐year outcomes in de novo renal transplant recipients receiving everolimus‐facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  N. Goto,et al.  Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation. , 2019, Transplantation proceedings.

[3]  A. Israni,et al.  OPTN/SRTR 2017 Annual Data Report: Kidney , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  Connie M. Rhee,et al.  Asian Americans & chronic kidney disease in a nationally representative cohort , 2019, BMC Nephrology.

[5]  W. Winkelmayer,et al.  Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996–2014) , 2018, American Journal of Nephrology.

[6]  A. Balas,et al.  Donor Specific Antibodies after Conversion from Mycophenolate Mofetil with Standard Exposure Tacrolimus to Everolimus with Tacrolimus Minimization in Stable Kidney Transplanted Recipients , 2018, Transplantation.

[7]  S. Chadban,et al.  Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. , 2018, Journal of the American Society of Nephrology : JASN.

[8]  F. Bemelman,et al.  Early Conversion From Calcineurin Inhibitor‐ to Everolimus‐Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  M. Woodward,et al.  Chronic kidney disease in Asia: Protocol for a collaborative overview , 2017, Nephrology.

[10]  F. Luan,et al.  Efficacy and Safety of Everolimus Plus Low‐Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard‐Dose Tacrolimus in De Novo Renal Transplant Recipients: 12‐Month Data , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  N. Goto,et al.  5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment. , 2016, International immunopharmacology.

[12]  M. Franco,et al.  Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  F. Passamonti,et al.  Everolimus in diffuse large B-cell lymphomas. , 2015, Future oncology.

[14]  C. Dromer,et al.  Evolution of donor‐specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors , 2014, Clinical transplantation.

[15]  S. Chadban,et al.  TrAnsFOrM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation , 2014 .

[16]  V. Jha,et al.  Chronic kidney disease: global dimension and perspectives , 2013, The Lancet.

[17]  S. Takahara,et al.  Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results , 2013, Transplantation research.

[18]  L. Rostaing,et al.  Incidence of donor‐specific antibodies in kidney transplant patients following conversion to an everolimus‐based calcineurin inhibitor‐free regimen , 2013, Clinical transplantation.

[19]  R. Walker,et al.  Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation , 2013, Transplantation.

[20]  T. Larson,et al.  Identification and Characterization of Kidney Transplants With Good Glomerular Filtration Rate at 1 Year But Subsequent Progressive Loss of Renal Function , 2012, Transplantation.

[21]  K. Budde,et al.  Donor‐Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  E. Paoletti,et al.  Effect of Everolimus on Left Ventricular Hypertrophy of De Novo Kidney Transplant Recipients: A 1 Year, Randomized, Controlled Trial , 2012, Transplantation.

[23]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[24]  A. Harraz,et al.  Controversies related to living kidney donors , 2011, Arab journal of urology.

[25]  D. Brennan,et al.  Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  J. Chapman.  Chronic Calcineurin Inhibitor Nephrotoxicity—Lest We Forget , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  A. Israni,et al.  The relationship between kidney function and long-term graft survival after kidney transplant. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  M. Zeier,et al.  Calcineurin inhibitor sparing regimens using m‐target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation? , 2011, Transplant international : official journal of the European Society for Organ Transplantation.

[29]  Nina Singh,et al.  Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens , 2005, Current opinion in infectious diseases.

[30]  F. Delmonico,et al.  Living-donor kidney transplantation: a review of the current practices for the live donor. , 2005, Journal of the American Society of Nephrology : JASN.

[31]  E. Tuzcu,et al.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.

[32]  Hua Yang,et al.  Tacrolimus enhances transforming growth factor-&bgr;1 expression and promotes tumor progression , 2003, Transplantation.

[33]  M. Lagman,et al.  Cyclosporine induces cancer progression by a cell-autonomous mechanism , 1999, Nature.

[34]  T. Meerloo,et al.  SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. , 1997, Transplantation.